Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index; 19 of the 36 sources its claims cite were checked for support.
Abstract
BACKGROUND: Diabetes mellitus is associated with an increased risk of cardiovascular events. Aspirin use reduces the risk of occlusive vascular events but increases the risk of bleeding; the balance of benefits and hazards for the prevention of first cardiovascular events in patients with diabetes is unclear. METHODS: We randomly assigned adults who had diabetes but no evident cardiovascular disease to receive aspirin at a dose of 100 mg daily or matching placebo. The primary efficacy outcome was the first serious vascular event (i.e., myocardial infarction, stroke or transient ischemic attack, or death from any vascular cause, excluding any confirmed intracranial hemorrhage). The primary safety outcome was the first major bleeding event (i.e., intracranial hemorrhage, sight-threatening bleeding event in the eye, gastrointestinal bleeding, or other serious bleeding). Secondary outcomes included gastrointestinal tract cancer. RESULTS: A total of 15,480 participants underwent randomization. During a mean follow-up of 7.4 years, serious vascular events occurred in a significantly lower percentage of participants in the aspirin group than in the placebo group (658 participants [8.5%] vs. 743 [9.6%]; rate ratio, 0.88; 95% confidence interval [CI], 0.79 to 0.97; P=0.01). In contrast, major bleeding events occurred in 314 participants (4.1%) in the aspirin group, as compared with 245 (3.2%) in the placebo group (rate ratio, 1.29; 95% CI, 1.09 to 1.52; P=0.003), with most of the excess being gastrointestinal bleeding and other extracranial bleeding. There was no significant difference between the aspirin group and the placebo group in the incidence of gastrointestinal tract cancer (157 participants [2.0%] and 158 [2.0%], respectively) or all cancers (897 [11.6%] and 887 [11.5%]); long-term follow-up for these outcomes is planned. CONCLUSIONS: Aspirin use prevented serious vascular events in persons who had diabetes and no evident cardiovascular disease at trial entry, but it also caused major bleeding events. The absolute benefits were largely counterbalanced by the bleeding hazard. (Funded by the British Heart Foundation and others; ASCEND Current Controlled Trials number, ISRCTN60635500 ; ClinicalTrials.gov number, NCT00135226 .).
Overview
CoChat Summary
TL;DR
In adults with diabetes and no evident cardiovascular disease, low-dose aspirin reduced serious vascular events but increased major bleeding, with absolute benefits largely counterbalanced by bleeding hazards. Aspirin did not reduce gastrointestinal or overall cancer incidence over a mean follow-up of 7.4 years.
Key findings
- Serious vascular events occurred in 658 aspirin-group participants (8.5%) vs. 743 placebo-group participants (9.6%) (rate ratio, 0.88; 95% CI, 0.79 to 0.97; P=0.01).
- Major bleeding occurred in 314 aspirin-group participants (4.1%) vs. 245 placebo-group participants (3.2%) (rate ratio, 1.29; 95% CI, 1.09 to 1.52; P=0.003), mostly gastrointestinal and other extracranial bleeding.
- No significant between-group difference was found for gastrointestinal tract cancer (157 [2.0%] vs. 158 [2.0%]) or any cancer (897 [11.6%] vs. 887 [11.5%]).
- Absolute effects: 91 patients would need to be treated to avoid a serious vascular event over 7.4 years, and 112 to cause a major bleeding event.
Methods
- Randomized trial of 15,480 adults with diabetes but no evident cardiovascular disease, assigned to aspirin 100 mg daily or matching placebo; factorial assignment also included n-3 fatty acids or placebo.
- Primary efficacy outcome was first serious vascular event (myocardial infarction, stroke or transient ischemic attack, or vascular death, excluding confirmed intracranial hemorrhage); primary safety outcome was first major bleeding event.
- Intention-to-treat time-to-event analyses used log-rank methods; mean follow-up was 7.4 years, with estimated mean adherence 70% in each group.
Limitations
- Stated: analyses for cancer had limited statistical power to detect hypothesized effects, and longer-term follow-up is planned or being continued.
- Stated: intention-to-treat analyses underestimate the effects of actual aspirin use because adherence was incomplete; secondary and exploratory outcomes were not adjusted for multiple comparisons, so confidence intervals should not be used to infer definitive subgroup or secondary effects.
- Evident from the text: participants were predominantly white (96.5%), had type 2 diabetes (94.1%), were recruited in the United Kingdom, and were well treated with cardioprotective therapies (e.g., 75.6% statin use in the aspirin group), which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
14 Valid · 1 Not valid · 4 Not checked · 53 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Aspirin use reduces the risk of occlusive vascular events but increases the risk of bleeding; the balance of benefits and hazards for the prevention of first cardiovascular events in patients with diabetes is unclear.”
What the sources say
- Supportedcites [1] 1. Antithrombotic Trialists' Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-60. source
The Results report fewer serious vascular events with aspirin in both primary and secondary prevention trials. The Abstract’s Interpretation explicitly describes a reduction in occlusive events, while noting that bleeding risk must be weighed against this benefit in primary prevention. (LLM, conf=0.94)
- Supportedcites [2] 2. Smith SC Jr, Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 2011; 124: 2458-73. source
The Antiplatelet agents/anticoagulants recommendations (page not provided) recommend aspirin for patients with coronary artery disease and state that it reduces saphenous vein graft closure after bypass surgery. This supports the attributed claim that aspirin reduces occlusive vascular events in the guideline’s secondary-prevention setting; the separate statement about first events in diabetes is not part of the quoted claim. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“On average, however, the approximate 50% higher risk of bleeding with aspirin use than with control counterbalanced much of the benefit in these low-risk patients.”
What the sources say
- Supportedcites [1] 1. Antithrombotic Trialists' Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-60. source
The Results report about a 50% increase in major gastrointestinal and other extracranial bleeding with aspirin in primary-prevention trials (RR 1.54). The Discussion says aspirin’s absolute benefits are much smaller in primary than in secondary prevention and that its benefits and bleeding hazards can be approximately balanced, supporting the claim about low-risk patients. (LLM, conf=0.93)
plainstates a causen = 95,000- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Only approximately 4% of participants in those trials had diabetes, and the lower relative risk among them was similar to that observed among participants without diabetes (as was also observed in the context of secondary prevention).”
What the sources say
- Partly supportedcites [1] 1. Antithrombotic Trialists' Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-60. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says that, in the primary-prevention trials, the proportional reduction in serious vascular events did not differ significantly by history of diabetes. This supports the main comparison, but the passages do not establish the citing sentence’s approximately 4% figure or its diabetes-specific comparison in secondary prevention. (LLM, conf=0.82)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The 2009 Antithrombotic Trialists' Collaboration meta-analysis involving 95,000 patients in six primary prevention trials showed that assignment to aspirin use led to a 12% (95% confidence interval [CI], 6 to 18) lower risk of serious vascular events than control. 1”
What the sources say
- Supportedcites [1] 1. Antithrombotic Trialists' Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-60. source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
plainstates a causen = 95,000- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Aspirin use reduces the risk of occlusive vascular events but increases the risk of bleeding; the balance of benefits and hazards for the prevention of first cardiovascular events in patients with diabetes is unclear.”
What the sources say
- Supportedcites [1] 1. Antithrombotic Trialists' Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-60. source
The Results report that aspirin increased major gastrointestinal and other extracranial bleeds in primary prevention trials, with a significant excess of major bleeds also observed in secondary prevention trials. This supports the attributed claim that aspirin increases bleeding risk. (LLM, conf=0.94)
- Partly supportedcites [2] 2. Smith SC Jr, Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 2011; 124: 2458-73. sourceExperimental — accuracy not yet measured
The Antiplatelet agents/anticoagulants recommendations (page unavailable) state that warfarin used with aspirin and/or clopidogrel is associated with increased bleeding risk. The References also list a study of bleeding complications at different aspirin doses, but the guideline passage does not establish the unqualified claim that aspirin use alone increases bleeding risk. (LLM, conf=0.81)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
37 more claims · 6 with their cited sources checked
Create a free account to see all 72 claims and every source verdict.
- It may state two separate claims as one. 16
- Probably not a substantial claim. 19
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The benefit of ASA in the ASCEND trial was observed on top of statins (75% of patients) and/or anti-hypertensive (∼60% of patients) drugs.292”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [292]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For people > 70 years of age (with or without diabetes), the balance appears to have greater risk than bene fi t (144,146).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [144]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“however, the ASCEND trial found benefit of low-dose aspirin in those in this weight range, which would not validate this suggested hypothesis (179).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [179]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For people >70 years of age (with or without diabetes), the balance appears to have greater risk than benefit (179,181).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [179]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“There were no significant differences by sex, weight, or duration of diabetes or other baseline factors, including ASCVD risk score.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [179]
Experimental — accuracy not yet measured
17 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
The Emerging Risk Factors Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)60484-9 · Cited by 5,125
Beta blockade during and after myocardial infarction: An overview of the randomized trials
Yusuf, S., Peto, R., Lewis, J., Collins, R., & Sleight, P. (1985) · Progress in Cardiovascular Diseases · doi:10.1016/s0033-0620(85)80003-7 · Cited by 3,205
Rivaroxaban with or without aspirin in stable cardiovascular disease
Eikelboom, J. W., Connolly, S. J., Bosch, J., Dagenais, G. R., Hart, R. G., Shestakovska, O., Diaz, R., Alings, M., Lonn, E. M., Anand, S. S., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709118 · Cited by 2,438
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1976) · British Journal of Cancer · doi:10.1038/bjc.1976.220 · Cited by 2,294
Smith, S. C., Benjamin, E. J., Bonow, R. O., Braun, L. T., Creager, M. A., Franklin, B. A., Gibbons, R. J., Grundy, S. M., Hiratzka, L. F., Jones, D. W., et al. (2011) · Circulation · doi:10.1161/cir.0b013e318235eb4d · Cited by 1,759
Rothwell, P. M., Fowkes, F. G. R., Belch, J. F., Ogawa, H., Warlow, C. P., & Meade, T. W. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62110-1 · Cited by 1,497
Rothwell, P. M., Wilson, M., Elwin, C.-E., Norrving, B., Algra, A., Warlow, C. P., & Meade, T. W. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61543-7 · Cited by 1,351
Rothwell, P. M., Wilson, M., Price, J. F., Belch, J. F., Meade, T. W., & Mehta, Z. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60209-8 · Cited by 984
Cited by
Items 201–300 of 1,171
Cardiovascular complications of systemic sclerosis: What to look for
Mani, P., Gonzalez, D., Chatterjee, S., & Faulx, M. D. (2019) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.86a.18109 · Cited by 33
Christiansen, M., Grove, E. L., & Hvas, A. (2021) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0041-1726096 · Cited by 32
Cyclooxygenase Inhibitors and Cancer: The Missing Pieces
Patrono, C. (2023) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.122.001631 · Cited by 30
Haykal, T., Barbarawi, M., Zayed, Y., Yelangi, A., Dhillon, H., Goranta, S., Kheiri, B., Chahine, A., Samji, V., Kerbage, J., et al. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-02932-0 · Cited by 31
Honigberg, M. C., Lander, B. S., Baliyan, V., Jones‐O’Connor, M., Healy, E. W., Scholtz, J., Nagurney, J. T., Hoffmann, U., Ghoshhajra, B. B., & Natarajan, P. (2019) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2019.04.021 · Cited by 29
Jourdi, G., Godiér, A., Lordkipanidzé, M., Marquis‐Gravel, G., & Gaussem, P. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.805525 · Cited by 38
High-Risk Coronary Plaque Features: A Narrative Review
Dawson, L. P., & Layland, J. J. (2022) · Cardiology and Therapy · doi:10.1007/s40119-022-00271-9 · Cited by 34
Judge, C. S., Ruttledge, S., Murphy, R., Loughlin, E. A., Gorey, S., Costello, M. M., Nolan, A. M., Ferguson, J. P., Halloran, M. O., O'Canavan, M., et al. (2019) · International Journal of Stroke · doi:10.1177/1747493019858780 · Cited by 32
Valensi, P. E., & Meune, C. (2019) · Herz · doi:10.1007/s00059-019-4798-3 · Cited by 33
Christiansen, M., Grove, E. L., & Hvas, A. (2019) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0039-1687905 · Cited by 33
Cykert, S., Keyserling, T. C., Pignone, M. P., DeWalt, D. A., Weiner, B. J., Trogdon, J. G., Wroth, T. H., Halladay, J. R., Mackey, M., Fine, J. P., et al. (2020) · Health Services Research · doi:10.1111/1475-6773.13571 · Cited by 34
Whelton, S. P., Berning, P., Blumenthal, R. S., Marshall, C. H., Martin, S. S., Mortensen, M. B., Blaha, M. J., & Dzaye, O. D. A. (2021) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.02.003 · Cited by 30
Platelets: the point of interconnection among cancer, inflammation and cardiovascular diseases
Camilli, M., Iannaccone, G., Vecchia, G. L., Cappannoli, L., Scacciavillani, R., Minotti, G., Massetti, M., Crea, F., & Aspromonte, N. (2021) · Expert Review of Hematology · doi:10.1080/17474086.2021.1943353 · Cited by 31
Small-vessel disease in the brain
Singh, A., Bonnell, G., Prey, J. D., Buchwald, N., Eskander, K., Kincaid, K. J., & Wilson, C. (2023) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2023.100277 · Cited by 43
Pros and cons of antithrombotic therapy in end-stage kidney disease: a 2019 update
Burlacu, A., Genovesi, S., Ortíz, A., Combe, C., Basile, C., Schneditz, D., SANDE, F. M. V. D., Popa, G. T., Moroșanu, C., & Covic, A. C. (2019) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfz040 · Cited by 31
Fifty years of research on antithrombotic therapy: Achievements and disappointments
Hirsh, J., Eikelboom, J. W., & Chan, N. (2019) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2019.10.023 · Cited by 29
Bhatt, D. L., Fox, K., Harrington, R. A., Leiter, L. A., Mehta, S. R., Simon, T., Andersson, M., Himmelmann, A., Ridderstråle, W., Held, C., et al. (2019) · Clinical Cardiology · doi:10.1002/clc.23164 · Cited by 26
Cardiac Computed Tomography for Personalized Management of Patients With Type 2 Diabetes Mellitus
Cardoso, R. N., Dudum, R., Ferraro, R., Bittencourt, M. S., Blankstein, R., Blaha, M. J., Nasir, K., Rajagopalan, S., Michos, E. D., Blumenthal, R. S., et al. (2020) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.120.011365 · Cited by 28
Gallagher, H., Dumbleton, J., Maishman, T., Whitehead, A. L., Moore, M. V., Fuat, A., Fitzmaurice, D. A., Henderson, R. A., Lord, J., Griffith, K. E., et al. (2022) · Trials · doi:10.1186/s13063-022-06132-z · Cited by 26
Thromboxane biosynthesis and future events in diabetes: the ASCEND trial
Petrucci, G., Buck, G. A. N., Rocca, B., Parish, S., Baigent, C., Hatem, D., Mafham, M. M., Habib, A., Bowman, L. J., Armitage, J., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehad868 · Cited by 30
Lee, D., Chun, E. J., Oh, T. J., Kim, K. M., Moon, J. H., Choi, S. H., Park, K. S., Jang, H. C., & Lim, S. K. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13667 · Cited by 27
Residual cardiovascular risk among people with diabetes
Dash, S., & Leiter, L. A. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13646 · Cited by 27
The Future of Clinical Trial Design: The Transition from Hard Endpoints to Value-Based Endpoints
Kruizinga, M. D., Stuurman, F. E., Groeneveld, G. J., & Cohen, A. F. (2019) · Handbook of experimental pharmacology · doi:10.1007/164_2019_302 · Cited by 28
Cardiovascular Disease Prevention and Therapy in Women With Type 2 Diabetes
Cocchi, C., Coppi, F., Farinetti, A., & Mattioli, A. V. (2021) · Future Cardiology · doi:10.2217/fca-2021-0011 · Cited by 27
Could Lipoxins Represent a New Standard in Ischemic Stroke Treatment?
Tułowiecka, N., Kotlęga, D., Bohatyrewicz, A., & Szczuko, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22084207 · Cited by 25
Clinical Management of Thrombotic Antiphospholipid Syndrome
Tumian, N. R., & Hunt, B. J. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11030735 · Cited by 49
Selak, V., Jackson, R., Poppe, K., Wu, B., Harwood, M. L. N., Grey, C., Pylypchuk, R. D., Mehta, S., Choi, Y. C., Kerr, A., et al. (2019) · Annals of Internal Medicine · doi:10.7326/m19-1132 · Cited by 26
Kidney disease trials for the 21st century: innovations in design and conduct
Herrington, W. G., Staplin, N., & Haynes, R. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0212-x · Cited by 28
Estándares SEA 2019 para el control global del riesgo cardiovascular
Mostaza, J. M., Pintó, X., Armario, P., Masana, L., Ascaso, J. F., Valdivielso, P., Velilla, T. A., Brea, Á., Calmarza, P., Cebollada, J., et al. (2019) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2019.03.004 · Cited by 82
Aspirin for the primary prevention of cardiovascular disease: latest evidence
Capodanno, D., Ingala, S., Calderone, D., & Angiolillo, D. J. (2019) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2019.1651199 · Cited by 26
Decrements in health‐related quality of life associated with adverse events in people with diabetes
Keng, M. J., Leal, J., Bowman, L. J., Armitage, J., Mihaylova, B., & ASCEND Study Collaborative Group (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14610 · Cited by 26
Wintzer-Wehekind, J., Alperi, A., Houde, C., Côté, J., Guimaraes, L. D. F. C., Côté, M., & Rodés‐Cabau, J. (2019) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2019.01.043 · Cited by 25
“Doctor, Should I Keep Taking an Aspirin a Day?”
Fernandes, A. A., McEvoy, J. W., & Halvorsen, S. (2019) · New England Journal of Medicine · doi:10.1056/nejmclde1903004 · Cited by 24
Cerebro‐renal interaction and stroke
Shah, B., Jagtap, P., Sarmah, D., Datta, A., Raut, S., Sarkar, A., Bohra, M., Singh, U., Baidya, F., Kalia, K., et al. (2020) · European Journal of Neuroscience · doi:10.1111/ejn.14983 · Cited by 28
Current Antithrombotic Treatments for Cardiovascular Diseases: A Comprehensive Review
Galanti, K., Marino, M. D., Mansour, D., Testa, S., Rossi, D., Scollo, C., Magnano, R., Pezzi, L., D’Alleva, A., Forlani, D., et al. (2024) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2508281 · Cited by 27
Maggi, P., Socio, G. V. D., Cicalini, S., D’Abbraccio, M., d’Ettorre, G., Biagio, A. D., Martinelli, C. V., Nunnari, G., Rusconi, S., Sighinolfi, L., et al. (2019) · AIDS Research and Therapy · doi:10.1186/s12981-019-0226-2 · Cited by 25
Diabetes and Vascular Disease: Is It All About Glycemia?
Vecchié, A., Montecucco, F., Carbone, F., Dallegri, F., & Bonaventura, A. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190830181944 · Cited by 24
Pallikadavath, S., Ashton, L., Brunskill, N. J., Burton, J. O., Gray, L. J., & Major, R. (2021) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab132 · Cited by 24
Pistrosch, F., Matschke, J. B., Schipp, D., Schipp, B., Henkel, E., Weigmann, I., Sradnick, J., Bornstein, S. R., Birkenfeld, A. L., & Hanefeld, M. (2021) · Diabetologia · doi:10.1007/s00125-021-05562-9 · Cited by 24
Aspirin in Primary Prevention: What Changed? A Critical Appraisal of Current Evidence
Dasa, O., Pepine, C. J., & Pearson, T. A. (2020) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2020.11.014 · Cited by 24
Wolfe, R. S., Broder, J. C., Zhou, Z., Murray, A. M., Ryan, J. L., Chan, A. T., Nelson, M. R., Woods, R. L., Ernst, M. E., Orchard, S. G., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf514 · Cited by 30
Association Between Long-Term Aspirin Use and Frailty in Men: The Physicians’ Health Study
Orkaby, A. R., Yang, L., Dufour, A. B., Travison, T. G., Sesso, H. D., Driver, J. A., Djoussé, L., & Gaziano, J. M. (2020) · The Journals of Gerontology Series A · doi:10.1093/gerona/glaa233 · Cited by 25
Relation of Pre‐Stroke Aspirin Use With Cerebral Infarct Volume and Functional Outcomes
Ryu, W., Schellingerhout, D., Hong, K., Jeong, S., Kim, B. J., Kim, J., Lee, K. B., Park, T. H., Park, S., Park, J., et al. (2021) · Annals of Neurology · doi:10.1002/ana.26219 · Cited by 24
Keng, M. J., Leal, J., Mafham, M. M., Bowman, L. J., Armitage, J., & Mihaylova, B. (2021) · Value in Health · doi:10.1016/j.jval.2021.09.005 · Cited by 26
Fat and fatty acids – a scoping review for Nordic Nutrition Recommendations 2023
Retterstøl, K., & Rosqvist, F. (2024) · Food & Nutrition Research · doi:10.29219/fnr.v68.9980 · Cited by 29
Sugawara, M., Gotō, Y., Yamazaki, T., Teramoto, T., Oikawa, S., Shimada, K., Uchiyama, S., Ando, K., Ishizuka, N., Murata, M., et al. (2018) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-018-0313-0 · Cited by 22
Siasos, G., Skotsimara, G., Oikonomou, E. K., Sagris, Μ., Mystakidi, V. C., Bletsa, E., Stampouloglou, P. K., Theofilis, P., Charalampous, G., & Tousoulis, D. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200417145605 · Cited by 23
Lin, Y., Chen, Y., Yuan, J., Qin, H., Dong, S., & Chen, Q. (2021) · BMJ Open · doi:10.1136/bmjopen-2021-048719 · Cited by 22
Stroke Prevention in Older Adults: Recent Advances.
Spence, J. D., Azarpazhooh, M. R., Larsson, S. C., Bogiatzi, C., & Hankey, G. J. (2020) · PubMed · doi:10.1161/strokeaha.120.031707 · Cited by 27
Armario, P., Brotons, C., Elosúa, R., de Leciñana, M. A., Castro, A., Clarà, A. B. I., Cortés, O., Rodríguez, Á. D., Herranz, M., Justo, S., et al. (2021) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2021.02.001 · Cited by 22
Wang, M., Yu, H., Li, Z., Gong, D.-X., & Liu, X. (2022) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-022-00537-6 · Cited by 23
Managing thrombotic risk in patients with diabetes
Camm, A. J., Sabbour, H. M., Schnell, O., Summaria, F., & Verma, A. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01581-x · Cited by 28
Zoungas, S., Zhou, Z., Owen, A. J., Curtis, A. J., Espinoza, S. E., Ernst, M. E., Woods, R. L., Orchard, S. G., McNeil, J. J., Murray, A. M., et al. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00327-3 · Cited by 23
A Practical Approach to Low-Dose Aspirin for Primary Prevention
Chiang, K. F., Shah, S., & Stafford, R. S. (2019) · JAMA · doi:10.1001/jama.2019.8388 · Cited by 22
Hwang, I., Lee, H., Yoon, Y. E., Choi, I.-S., Kim, H., Chang, H., Lee, J. Y., Choi, J. A., Kim, H. J., Cho, G., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.09.018 · Cited by 24
Mæng, M., Steg, P. G., Bhatt, D. L., Hohnloser, S. H., Nordaby, M., Miede, C., Kimura, T., Lip, G. Y. H., Oldgren, J., ten Berg, J. M., et al. (2019) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2019.07.059 · Cited by 24
Caldeira, D., Alves, M., David, C., Costa, J. N., Ferreira, J. J., & Pinto, F. J. (2019) · Primary care diabetes · doi:10.1016/j.pcd.2019.11.004 · Cited by 24
Wein, T. H., Lindsay, M. P., Gladstone, D. J., Poppe, A. Y., Bell, A., Casaubon, L. K., Foley, N. C., Coutts, S. B., Cox, J. L., Douketis, J. D., et al. (2020) · Canadian Medical Association Journal · doi:10.1503/cmaj.191599 · Cited by 20
Komajda, M., Cosentino, F., Ferrari, R., Kernéis, M., Kosmachova, E., Laroche, C., Maggioni, A. P., Rittger, H., Steg, P. G., Szwed, H., et al. (2020) · European Journal of Preventive Cardiology · doi:10.1177/2047487320912491 · Cited by 23
Self-citationcGMP Signaling in Cardiovascular Diseases: Linking Genotype and Phenotype
Dang, T. A., Schunkert, H., & Kessler, T. (2020) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000744 · Cited by 24
Anti-thrombotic strategies in elderly patients receiving platelet inhibitors
Schäfer, A., Flierl, U., & Bauersachs, J. K. (2019) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvz032 · Cited by 22
Rychen, J., Saemann, A., Fingerlin, T. J., Guzman, R. G., Mariani, L., Greuter, L., & Soleman, J. (2022) · Acta Neurochirurgica · doi:10.1007/s00701-022-05416-2 · Cited by 22
Nafisi, S., Støer, N. C., Veierød, M. B., Randel, K. R., Hoff, G. S., Löfling, L., Bosetti, C., & Botteri, E. (2024) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002695 · Cited by 21
Embracing the polypill as a cardiovascular therapeutic: is this the best strategy?
Franczyk, B., Gluba-Brzózka, A., Jurkiewicz, Ł., Penson, P. E., Banach, M., & Rysz, J. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1532501 · Cited by 23
Shah, R., Khan, B., Latham, S. B., Khan, S., & Rao, S. V. (2019) · The American Journal of Medicine · doi:10.1016/j.amjmed.2019.05.015 · Cited by 21
Perioperative management of antiplatelet therapy in noncardiac surgery
Filipescu, D. C., Ştefan, M., Văleanu, L., & Popescu, W. M. (2020) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0000000000000875 · Cited by 26
RIPK1 and RIPK3 inhibitors: potential weapons against inflammation to treat diabetic complications
Ke, D., Zhang, Z., Liu, J., Chen, P., Dai, Y., Sun, X., Chu, Y., & Li, L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1274654 · Cited by 22
McDermott, M., Khaing, P. H., Meah, M. N., Wang, K.-L., Craig, N. J., Loganath, K., Balmforth, C., van Beek, E. J. R., Norrie, J. D., McKinstry, B., et al. (2025) · JAMA Cardiology · doi:10.1001/jamacardio.2025.1763 · Cited by 21
Aspirin or P2Y12 inhibitor monotherapy in atherosclerotic cardiovascular disease?
Galli, M., ten Berg, J. M., Valgimigli, M., Capodanno, D., Gragnano, F., Kimura, T., Bhatt, D. L., Gibson, C. M., Mehran, R., & Angiolillo, D. J. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf718 · Cited by 26
Bias and Loss to Follow‐Up in Cardiovascular Randomized Trials: A Systematic Review
Fong, L. C. W., Ford, T. J., da Costa, B. R., Jüni, P., & Berry, C. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.015361 · Cited by 19
Aspirin for prevention of colorectal cancer in the elderly: friend or foe?
Perisetti, A., Goyal, H., Tharian, B., Inamdar, S., & Mehta, J. L. (2020) · Annals of Gastroenterology · doi:10.20524/aog.2020.0556 · Cited by 21
Impaired Clinical Efficacy of Aspirin in Hypoalbuminemic Patients With Diabetes Mellitus
Sciacqua, A., Andreozzi, F., Succurro, E., Pastori, D., Cammisotto, V., Armentaro, G., Mannino, G. C., Fiorentino, T. V., Pignatelli, P., Angiolillo, D. J., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.695961 · Cited by 20
Bi, J., Li, Q., Yang, Z., Cai, L., Lv, T., Yang, X., Yan, L., Liu, X., Wang, Q., Fu, X., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.687942 · Cited by 22
Gyldenkerne, C., Kahlert, J. A., Olesen, K. K. W., Thrane, P. G., Sørensen, H. T., Thomsen, R. W., & Mæng, M. (2022) · Diabetes Care · doi:10.2337/dc22-0440 · Cited by 23
A Contemporary Review of Antiplatelet Therapies in Current Clinical Practice
Arockiam, S., Staniforth, B., Kepreotis, S., Maznyczka, A., & Bulluck, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241311132 · Cited by 23
Trajectories of Adherence to Low-Dose Aspirin Treatment Among the French Population
AJROUCHE, A., Estellat, C., Rycke, Y. D., & Tubach, F. (2019) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248419865287 · Cited by 20
The dilemma of aspirin resistance in obese patients
Ardeshna, D. R., Khare, S., Jagadish, P. S., Bhattad, V. B., Cave, B. E., & Khouzam, R. N. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.07.52 · Cited by 23
Nudy, M. S., Cooper, J., Ghahramani, M., Ruzieh, M., Mandrola, J. M., & Foy, A. (2020) · The American Journal of Medicine · doi:10.1016/j.amjmed.2020.04.028 · Cited by 20
Chazova, I. E., Shestakova, M. V., Zhernakova, Y. V., Blinova, N. V., Маркова, Т. Н., Mazurina, N. V., Владиславович, Е. М., Tereshchenko, S. N., Жиров, И. В., Komarov, A. L., et al. (2021) · Eurasian heart journal · doi:10.38109/2225-1685-2021-2-6-61 · Cited by 25
Liu, C., Du, L., Zhang, S., Wang, H., Kong, L., & Du, G. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1108518 · Cited by 20
Zhou, W., Zhao, H.-W., Chen, H., et al. (2019) · CrystEngComm · doi:10.1039/c9ce00377k · Cited by 19
Diabetes mellitus associated neurovascular lesions in the retina and brain: A review
Sinclair, S. H., Miller, E. S., Talekar, K. S., & Schwartz, S. S. (2022) · Frontiers in Ophthalmology · doi:10.3389/fopht.2022.1012804 · Cited by 22
Bertero, E., Carmisciano, L., Jonasson, C., Butler, J., Maack, C., & Ameri, P. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae089 · Cited by 18
Khan, S. U., Asad, Z. U. A., Khan, M. U., Talluri, S., Ali, F., Khan, M. S., Lone, A. N., Mookadam, F., Krasuski, R. A., & Kaluski, E. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319825510 · Cited by 24
Clinician's Guide to the Updated ABCs of Cardiovascular Disease Prevention: A Review Part 1
Arps, K. E., Pallazola, V. A., Cardoso, R. N., Meyer, J., Jones, R., Latina, J. M., Gluckman, T. J., Stone, N. J., Blumenthal, R. S., & McEvoy, J. W. (2019) · The American Journal of Medicine · doi:10.1016/j.amjmed.2019.01.016 · Cited by 22
Rodríguez, L. A. G., Lanas, Á., Soriano‐Gabarró, M., & Soriano, L. C. (2019) · Annals of Medicine · doi:10.1080/07853890.2019.1591635 · Cited by 25
Raggi, P. (2019) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2019.08.009 · Cited by 18
Looking back and thinking forwards — 15 years of cardiology and cardiovascular research
Kalman, J. M., Lavandero, S., Mahfoud, F., Nahrendorf, M., Yacoub, M. H., & Zhao, D. H. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0261-7 · Cited by 17
Aging and HIV infection: focus on cardiovascular disease risk.
Aberg, J. A. (2020) · PubMed · Cited by 31
Antithrombotic Therapy: Prevention and Treatment of Atherosclerosis and Atherothrombosis
Olie, R. H., van der Meijden, P. E. J., Spronk, H. M. H., & Cate, H. T. (2020) · Handbook of experimental pharmacology · doi:10.1007/164_2020_357 · Cited by 21
Valensi, P. E., Henry, P., Boccara, F., Cosson, E., Prévost, G., Emmerich, J., Ernande, L., Marcadet, D. M., Mousseaux, É., Rouzet, F., et al. (2020) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2020.07.003 · Cited by 21
Diabetes and cardiovascular disease in older adults
Bilal, A., & Pratley, R. E. (2024) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.15259 · Cited by 21
Lüscher, T. F., Davies, A. J., Beer, J. H., Valgimigli, M., Nienaber, C. A., Camm, A. J., Baumgärtner, I., Diener, H., & Konstantinides, S. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab642 · Cited by 21
Kautzky‐Willer, A., Leutner, M., Abrahamian, H., Frühwald, L., Hoppichler, F., Lechleitner, M., & Harreiter, J. (2023) · Wiener klinische Wochenschrift · doi:10.1007/s00508-023-02185-5 · Cited by 24
Gaengler, S., Sadlon, A., Molino, C. D. G. R. C., Willett, W. C., Manson, J. E., Vellas, B. J., Steinhagen‐Thiessen, E., von Eckardstein, A., Ruschitzka, F. T., Rizzoli, R., et al. (2024) · The journal of nutrition health & aging · doi:10.1016/j.jnha.2024.100037 · Cited by 19
Fernández‐Jiménez, R., Wang, T. J., Fuster, V., & Blot, W. J. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.013404 · Cited by 21
Pozo, L., Bello, F. O., Suárez, A., Ochoa-Martinez, F. E., Mendez, Y. H., Chang, C., & Surani, S. (2019) · World Journal of Diabetes · doi:10.4239/wjd.v10.i5.291 · Cited by 20
Expert consensus on the management of hypertension in the young and middle‐aged Chinese population
Liu, J., Lu, X.-Z., Chen, L., & Huo, Y. (2019) · International Journal of Clinical Practice · doi:10.1111/ijcp.13426 · Cited by 26
Muzurović, E. M., & Mikhailidis, D. P. (2020) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248420941675 · Cited by 17
Wu, Q., Yao, X., Chen, H., Liu, Z., Li, T., Fan, X., Zhang, G., Yu, L., Chen, M., Xu, C., et al. (2020) · Journal of Cancer · doi:10.7150/jca.49001 · Cited by 20
Metadata
- Authors
- The ASCEND Study Collaborative Group
- Affiliations
- MRC Population Health Research Unit (GB)
- Corresponding author
- The ASCEND Study Collaborative Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-10-18
- Volume
- 379
- Issue
- 16
- Pages
- 1529-1539
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2899755710
- Cited by
- 1,200
- References
- 23
- Citations by year
- 2026: 66 · 2025: 105 · 2024: 123 · 2023: 117 · 2022: 170 · 2021: 176 · 2020: 193 · 2019: 214 · 2018: 33
- FWCI
- 116.42
- Type
- journal article
- Language
- en
- Open access
- green
- ora.ox.ac.uk
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Oxford University Research Archive (ORA) (University of Oxford) (submittedVersion)
- Funders
- Mylan EPD
- Solvay Pharmaceuticals
- Bayer Schering
- British Heart Foundation (SP/03/02, SP/08/010/25939, SP/14/13/31114)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
- Keywords
- diabetes mellitus, aspirin, primary prevention, cardiovascular events, major bleeding, gastrointestinal bleeding, intracranial hemorrhage, myocardial infarction, stroke, cancer incidence, benefits and risks, ASCEND trial, occlusive vascular disease, antiplatelet therapy, cardiovascular risk reduction, gastrointestinal cancer, cancer mortality
- MeSH terms
- Aged, Aged, 80 and over, Aspirin, Cardiovascular Diseases, Diabetes Mellitus, Female, Follow-Up Studies, Hemorrhage, Humans, Male, Middle Aged, Platelet Aggregation Inhibitors, Primary Prevention, Risk Factors, Poisson Distribution, Diabetes Complications
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-16, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-16 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.